New hope for Atrial Fibrillation Patients with Kidney Disease
At the recent European Society of Cardiology (ESC) Congress 2019, study results from the RELOADED and CALLIPER studies were presented.
The evidence from these observational studies show the benefits of the non-vitamin K antagonist oral anti-coagulant (NOAC), rivaroxaban, in ensuring proper kidney function in atrial fibrillation patients with kidney disease as compared to vitamin-K antagonist anti-coagulant (VKA), phenprocoumon.
In the RELOADED study, the results were derived from the analysis of anonymized German healthcare claims data. Which involved a total of 22,339 non-valvular atrial fibrillation patients who took rivaroxaban and 23,552 patients who were treated with phenprocoumon.
A comparison between rivaroxaban and phenprocoumon showed 73 percent lower relative risk of patients with chronic kidney disease (CKD) when rivaroxaban was used. CKD patients who took rivaroxaban showed a 44 percent lower risk of acute kidney injury compared to CKD patients who were given phenprocoumon.
The CALLIPER study also displayed similar results with a 50 percent lower relative risk of patients with CKD aggravating their kidney function. This study result was derived from the US administrative claims database from 2012 to 2017, with a total of 7,372 AF patients.
These studies are established from existing real world evidence of rivaroxaban safety and efficiencies. Now confirming a further advantage of NOACs in reduced risk of kidney failure will benefit many elderly AF patients currently with kidney disease in Asia Pacific.